Lexicon Pharmaceuticals | LXRX - Operating Expenses


Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Illumina USD 899M 47M Jun/2026
Insmed USD 606.26M 79.46M Sep/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.93B 1.09B Sep/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 960M 817M Jun/2026
Novartis USD 10.2B 912M Jun/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025